source
- Definium's LSD candidate DT120 shows positive Phase 3 results, moving toward FDA submissionDefinium Therapeutics reported positive topline data from its Phase 3 Panorama trial of DT120, an oral LSD formulation for generalized anxiety disorder (GAD). The trial met its primary endpoint, s…
- GSK presents promising late-stage lung cancer data from two investigational drugsGSK highlighted late-stage results for two of its lung cancer candidates, reporting encouraging efficacy signals that could advance the programs toward regulatory review. The company shared the da…